It’s a new way to create “bi-paternal” mice that can survive to adulthood—but human applications are still a long way off.

Many CRISPR-based therapies use nucleases derived from bacteria. About 80% of people have pre-existing immunity to these proteins through everyday exposure to these bacteria, but scientists didn't ...

CRISPR's current valuation is attractive, with $1.9 billion in cash and expected revenue from Casgevy, making it a speculative but compelling buy. Editas and CRISPR are probably most closely ...

The concept of biological reproduction between same-sex individuals in mammals has always been deemed impossible. However, ...

If successful, these programs could dramatically expand the addressable market for CRISPR's therapies, as they would not require the complex ex vivo cell manipulation process needed for current ...

The most complex engineering of human cell lines ever has been achieved by scientists, revealing that our genomes are more ...

Until now, CRISPR has been used in trials as an ‘ex vivo’ technique to alter the expression of genes in cells in the lab, which can then be administered to patients as a cell therapy.

ZUG, Switzerland and BOSTON, Jan. 13, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...

Then Crispr came along—the elegant enzymatic apparatus that allows delivery of DNA scissors to a specific target in the genome. In December 2023, the FDA approved the first Crispr-based therapy ...

CRISPR gene editing is widely regarded as one of the most important leaps in biomedical and agricultural research, with ...